Tryton bifurcation lesion stent
This article was originally published in The Gray Sheet
Executive SummaryNewton, Mass.-based Tryton Medical enrolls one-third of its 30-patient, three-site European feasibility study for the Side-Branch stent, the firm announces Oct. 10. The balloon-expandable stent is used in conjunction with standard coronary stents to treat bifurcation lesions that split into vessels' side branches. The firm hopes to begin a pivotal trial for a drug-eluting version of the product - likely partnering to use a sirolimus derivative - within a year and a half, according to Tryton Chief Technical Officer Richard Davis. The product could reach the U.S. market as early as 2009, he said. According to Tryton, 540,000 procedures for bifurcation lesions are performed each year, representing 20% of all coronary lesions treated. The firm hopes Side-Branch will fill a gap in treatment options to become a new standard of care for these challenging cases...
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.